Product Name :
SKLB-197
Description:
SKLB-197 is a potent and highly selective ATR inhibitor. SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo. In addition, this compound exhibited good pharmacokinetic properties.
CAS:
2713577-16-1
Molecular Weight:
424.50
Formula:
C25H24N6O
Chemical Name:
Quinazoline, 2-(1H-indol-4-yl)-4-[(3R)-3-methyl-4-morpholinyl]-6-(1-methyl-1H-pyrazol-5-yl)-
Smiles :
CN1N=CC=C1C1=CC2=C(N=C(N=C2C=C1)C1C=CC=C2NC=CC=12)N1CCOC[C@H]1C
InChiKey:
FCNFJRRMUAOHKI-MRXNPFEDSA-N
InChi :
InChI=1S/C25H24N6O/c1-16-15-32-13-12-31(16)25-20-14-17(23-9-11-27-30(23)2)6-7-22(20)28-24(29-25)19-4-3-5-21-18(19)8-10-26-21/h3-11,14,16,26H,12-13,15H2,1-2H3/t16-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
SKLB-197 is a potent and highly selective ATR inhibitor. SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo. In addition, this compound exhibited good pharmacokinetic properties.|Product information|CAS Number: 2713577-16-1|Molecular Weight: 424.{{Cediranib} MedChemExpress|{Cediranib} Inducer|{Cediranib} NF-κB|{Cediranib} Protocol|{Cediranib} In Vitro|{Cediranib} custom synthesis} 50|Formula: C25H24N6O|Chemical Name: Quinazoline, 2-(1H-indol-4-yl)-4-[(3R)-3-methyl-4-morpholinyl]-6-(1-methyl-1H-pyrazol-5-yl)-|Smiles: CN1N=CC=C1C1=CC2=C(N=C(N=C2C=C1)C1C=CC=C2NC=CC=12)N1CCOC[C@H]1C|InChiKey: FCNFJRRMUAOHKI-MRXNPFEDSA-N|InChi: InChI=1S/C25H24N6O/c1-16-15-32-13-12-31(16)25-20-14-17(23-9-11-27-30(23)2)6-7-22(20)28-24(29-25)19-4-3-5-21-18(19)8-10-26-21/h3-11,14,16,26H,12-13,15H2,1-2H3/t16-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Custirsen} site|{Custirsen} Apoptosis|{Custirsen} Activator|{Custirsen} Protocol|{Custirsen} References|{Custirsen} custom synthesis} |Shelf Life: ≥12 months if stored properly.PMID:25429455 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Bin H, Chen P, Wu M, Wang F, Lin G, Pan S, Liu J, Mu B, Nan J, Huang Q, Li L, Yang S. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo. Eur J Med Chem. 2022 Mar 15;232:114187. doi: 10.1016/j.ejmech.2022.114187. Epub 2022 Feb 12. PMID: 35183872.Products are for research use only. Not for human use.|
